Physician profile
Dolores E Solis
NPI 1760676191
$1,719.60
in general payments reported to CMS, 2019-2025
14 companies · $290 in 2025
The $290 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $140 · 2023: $294 · 2024: $996 · 2025: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.59 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $416.35 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $317.67 | 2023-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $244.17 | 2023-2025 | |
| Alkermes, INC. | $141.51 | 2022-2025 | Aristada, Lybalvi |
| Novo Nordisk INC | $140.60 | 2024 | |
| Neurocrine Biosciences, INC. | $94.10 | 2023-2024 | Ingrezza |
| Janssen Pharmaceuticals, INC | $87.97 | 2022-2024 | Invega Sustenna |
| E.R. Squibb & Sons, L.L.C. | $76.32 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.63 | 2022-2024 | Caplyta |
| Indivior INC. | $51.26 | 2022-2023 | Perseris |
| Nevro Corp. | $40.09 | 2024 | Senza |
| Vanda Pharmaceuticals INC. | $26.24 | 2025 | Fanapt |
| Corium, LLC | $16.03 | 2024 | Azstarys |
| Glaxosmithkline, LLC. | $11.66 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dolores Solis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.